​​PhylonPS founder and owner Paul Kostenuik, PhD, has 35 years of R&D experience in academia and industry. As lead scientist on Amgen's denosumab program, Paul supported the molecule throughout its preclinical and clinical development programs, regulatory approval, and blockbuster commercial status. As an Amgen Scientific Director, he oversaw biomechanics and biomarker groups while researching and publishing in oncology, osteoporosis, orthopedics, immunology, cardiovascular disease, arthritis, muscle, kidney disease, pediatrics, and dental disease. One of Amgen's most collaborative and published scientists, Paul managed >150 industry-academia collaborations and has authored >120 peer-reviewed manuscripts. Dr. Kostenuik is also an Adjunct Professor at the University of Michigan School of Dentistry, where chairs the Industrial Technologies Board of an NIDCR-sponsored Regenerative Medicine Consortium. Additional non-profit organizations he supports include MiracleFeet (clubfoot treatment), the FD/MAS Alliance (Fibrous Dysplasia/McCune Albright Syndrome), and the Ventura County Industry Council. Paul  recently served as a contract Medical Director in
Amgen Global Medical Affairs; Vice President of Capital, Strategy, and Transactions at
​Radius Health; and Vice President of Translational Medicine at
​Angitia Biopharmaceuticals.